Literature DB >> 316725

Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.

C A Koller, B S Mitchell, M R Grever, E Mejias, L Malspeis, E N Metz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 316725

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  10 in total

1.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 2.  Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.

Authors:  R I Glazer
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

4.  Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

Authors:  D A Carson; D B Wasson; J Kaye; B Ullman; D W Martin; R K Robins; J A Montgomery
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.

Authors:  L W Brox; E Pollock; A Belch
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.

Authors:  A S Bagnara; M S Hershfield
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

7.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.

Authors:  B Ullman; D W Martin
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

Review 9.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.

Authors:  Y Kuroki; M Shimoyama; S Inaba; M Hirose
Journal:  Jpn J Cancer Res       Date:  1989-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.